Medical Facilities (DR) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Facility service revenue increased by 7.8% year-over-year to $63.1 million, driven by a favorable case mix weighted toward higher-value orthopedic and spine procedures.
Income from operations rose 9.4% to $9.6 million, and EBITDA increased 7.1% to $12.5 million compared to Q2 last year.
Surgical case volume declined 2.3%, but excluding low-margin dental cases, volumes were flat.
Approximately $17.1 million was returned to shareholders through the repurchase of 1,337,500 common shares during the quarter.
Financial highlights
Revenue for the quarter was $63.1 million, up 7.8% year-over-year.
Net income from continuing operations was $5.7 million, down 17.5% year-over-year, mainly due to non-cash finance costs and income tax variations.
EBITDA was $12.5 million, up 7.1% from the prior year.
Consolidated cash balance at quarter end was $64.1 million, with a corporate cash balance of $58.0 million.
Distributable cash flow for Q2 was C$4.3 million, with a payout ratio of 33.9%.
Outlook and guidance
Active recruitment campaigns are underway to attract additional pain physicians and orthopedic surgeons to boost volumes.
Management remains focused on maximizing shareholder value and continues to evaluate opportunities for further value creation.
Strong liquidity position supports ongoing hospital operations and future capital returns.
Latest events from Medical Facilities
- Double-digit growth, strong liquidity, and active share buybacks drive value amid rising healthcare demand.DR
Investor update - Revenue up 10.8%, EBITDA up 13.8%, and cash boosted by $46M asset sale.DR
Q1 2026 - Delivers strong financials and shareholder returns through high-quality specialty surgical hospitals.DR
Investor presentation - Strong revenue and earnings growth, major asset sales, and buybacks boosted shareholder returns.DR
Q4 2025 - Q2 saw SFSH headwinds but strong net income growth and new $40M credit secured.DR
Q2 2025 - Revenue and EBITDA rose on strong case volumes; PPP loan forgiveness to boost Q3.DR
Q2 2024 - Q3 net income up 263% and revenue up 11.2%, driven by PPP loan forgiveness and case growth.DR
Q3 2024 - Revenue and EBITDA stable, net income up, and $44.3M returned to shareholders via buybacks.DR
Q1 2025 - Net income nearly doubled in 2024, fueled by asset sales and robust capital returns.DR
Q4 2024